Moricizine-induced proarrhythmia.

Moricizine is a Class I antiarrhythmic drug currently approved for the treatment of life-threatening ventricular arrhythmias. The drug has received significant attention because of its role in the Cardiac Arrhythmia Suppression Trial. Previous data suggested that the agent has a relatively low proarrhythmic potential.